Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 3/20 | 0.82 |
| ▸ | DNMT3A | Q9Y6K1 | 1/20 | 0.75 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.69 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11851297 | 0.91 | NLRP3 (0.82) | NLRP3DNMT3A | |
| SCHEMBL11752364 | 0.90 | NLRP3 (1.00) | NLRP3DNMT3AHDAC1HDAC6 | |
| SCHEMBL8993421 | 0.90 | NLRP3 (1.00) | NLRP3DNMT3AHDAC1HDAC6 | |
| SCHEMBL29397166 | 0.90 | NLRP3 (1.00) | NLRP3DNMT3AHDAC1HDAC6 | |
| SCHEMBL29623532 | 0.89 | NLRP3 (1.00) | NLRP3DNMT3A | |
| SCHEMBL20254183 | 0.89 | NLRP3 (1.00) | NLRP3DNMT3A | |
| SCHEMBL16261128 | 0.89 | NLRP3 (1.00) | NLRP3DNMT3A | |
| SCHEMBL29516883 | 0.89 | NLRP3 (1.00) | NLRP3DNMT3A | |
| SCHEMBL16261121 | 0.88 | NLRP3 (0.77) | NLRP3DNMT3A | |
| SCHEMBL4654235 | 0.88 | ABCC9 (0.72) | NLRP3DNMT3AHDAC1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10343985-B2 | Cryopyrin inhibitors for preventing and treating inflammation | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2019-07-09 | — | — | US | disclosed |
| US-10343985-B2 | Cryopyrin inhibitors for preventing and treating inflammation | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2019-07-09 | — | — | US | disclosed |
| WO-2018103583-A1 | N-HYDROXY-BENZENE-SULFONAMIDE DERIVATIVES AND THEIR USES THEREOF | ZIBO ANXUAN PHARMACEUTICAL SCIENCE AND TECHNOLOGY CO., LTD. (CN) | 2018-06-14 | — | — | WO | disclosed |
| US-20160052876-A1 | CRYOPYRIN INHIBITORS FOR PREVENTING AND TREATING INFLAMMATION | VIRGINIA COMMONWEALTH UNIVERSITY | 2016-02-25 | — | — | US | disclosed |
| US-7858647-B2 | N-[1,3,4]-thiadiazol-2-yl-benzene sulfonamides, pharmaceutical compositions thereof and methods for their therapeutic use | SANOFI-AVENTIS (FR) | 2010-12-28 | — | — | US | disclosed |
| US-7858647-B2 | N-[1,3,4]-thiadiazol-2-yl-benzene sulfonamides, pharmaceutical compositions thereof and methods for their therapeutic use | SANOFI-AVENTIS (FR) | 2010-12-28 | — | — | US | disclosed |
| US-7858647-B2 | N-[1,3,4]-thiadiazol-2-yl-benzene sulfonamides, pharmaceutical compositions thereof and methods for their therapeutic use | SANOFI-AVENTIS (FR) | 2010-12-28 | — | — | US | disclosed |
| US-20090054494-A1 | N-[1,3,4]-THIADIAZOL-2-YL-BENZENE SULFONAMIDES, PHARMACEUTICAL COMPOSITIONS THEREOF AND METHODS FOR THEIR THERAPEUTIC USE | SANOFI-AVENTIS (FR) | 2009-02-26 | — | — | US | disclosed |
| US-20090054494-A1 | N-[1,3,4]-THIADIAZOL-2-YL-BENZENE SULFONAMIDES, PHARMACEUTICAL COMPOSITIONS THEREOF AND METHODS FOR THEIR THERAPEUTIC USE | SANOFI-AVENTIS (FR) | 2009-02-26 | — | — | US | disclosed |
| US-20090054494-A1 | N-[1,3,4]-THIADIAZOL-2-YL-BENZENE SULFONAMIDES, PHARMACEUTICAL COMPOSITIONS THEREOF AND METHODS FOR THEIR THERAPEUTIC USE | SANOFI-AVENTIS (FR) | 2009-02-26 | — | — | US | disclosed |
| EP-1937657-A1 | N-[1 ,3,4]-THIADIAZOL-2-YL-BENZENE SULFONAMIDES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | Sanofi-Aventis (FR) | 2008-07-02 | — | — | EP | disclosed |
| WO-2007039175-A1 | N-[1 ,3,4]-THIADIAZOL-2-YL-BENZENE SULFONAMIDES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (DE) | 2007-04-12 | — | — | WO | disclosed |
| WO-2007039175-A1 | N-[1 ,3,4]-THIADIAZOL-2-YL-BENZENE SULFONAMIDES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (DE) | 2007-04-12 | — | — | WO | disclosed |
| US-3965173-A | MULTISTAGE, METHYLATION OF 5-CHLOROSALICYLIC ACID | CHUBB FRANCIS L | 1976-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10343985-B2 | Cryopyrin inhibitors for preventing and treating inflammation | IL1RN, SERPINB1, NFKBIA | NLRP3 11/4885DNMT3A 4558/4885HDAC1 2366/4885 |
| US-20090054494-A1 | N-[1,3,4]-THIADIAZOL-2-YL-BENZENE SULFONAMIDES, PHARMACEUTICAL COMPOSITIONS THEREOF AND METHODS FOR THEIR THERAPEUTIC USE | PPARD, PPARG, PPARA | NLRP3 2823/4885DNMT3A 4174/4885HDAC1 1889/4885 |
| US-20160052876-A1 | CRYOPYRIN INHIBITORS FOR PREVENTING AND TREATING INFLAMMATION | IL1RN, SERPINB1, NFKBIA | NLRP3 11/4885DNMT3A 4558/4885HDAC1 2366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.